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ABSTRACT 19 
Objectives: The treatment of skin infections caused by Staphylococcus aureus 20 
(S. aureus) is limited by acquired antibiotic resistance and poor drug delivery into 21 
pathogen and host cells. Here we investigated the antibacterial activities of six 22 
topically used antimicrobials and a cationic polymer, polyhexamethylene 23 
biguanide (PHMB), against intracellular MSSA, strain RN4420 and MRSA, 24 
strains EMRSA-15 and USA 300.  25 
Methods: The minimum inhibitory concentrations (MIC) of antimicrobials were 26 
determined against MSSA and MRSA strains, and the bactericidal activities of 27 
nadifloxacin and PHMB against intracellular MRSA were determined using 28 
infected keratinocytes. Fluorescein-tagged PHMB (PHMB-FITC) was used to 29 
study PHMB uptake, colocalisation with intracellular EMRSA-15 and retention in 30 
keratinocytes. The mechanism(s) of PHMB uptake into keratinocytes were 31 
studied using a dynamin inhibitor, dynasore.  32 
Results: Gentamicin, nadifloxacin and PHMB showed the lowest MIC values 33 
against MRSA. Nadifloxacin at 10 mg/L killed 80% of intracellular EMRSA-15, but 34 
was not effective against USA 300. PHMB at 4 mg/L killed almost 100% of 35 
intracellular EMRSA-15 and USA 300. PHMB entered keratinocytes, colocalised 36 
with intracellular EMRSA-15 and was retained by the cells for over five hours. 37 
PHMB uptake and its intracellular antibacterial activities were inhibited by the 38 
dynamin inhibitor, dynasore. 39 
Conclusion: PHMB kills intracellular MRSA via direct interaction with pathogens 40 
inside keratinocytes and host cell entry is dynamin dependent. 41 
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Skin infections caused by invasive pathogens start when outer skin structures 46 
are damaged due to injury, such as a burn,1 or skin diseases, such as atopic 47 
dermatitis.2 The majority of invasive skin infections are caused by S. aureus, 48 
including MRSA.3 Invasive strains of S. aureus are difficult to manage 49 
therapeutically due to their thick cell barriers and acquired drug resistance. 50 
Additionally, S. aureus is able to gain entry and replicate within various host cell 51 
types, including keratinocytes, macrophages, endothelial cells, epithelial cells, 52 
fibroblasts, and osteoblasts, where antibiotic concentrations in situ are often sub- 53 
therapeutic.4 Recent work by Lehar et al, demonstrated that the three major 54 
antibiotics that are currently administered for invasive MRSA infections (linezolid, 55 
vancomycin, and daptomycin) fail to kill intracellular S. aureus USA 300 in 56 
infected mice.5 Consequently, intracellular invasion of mammalian cells by S. 57 
aureus can induce pyroptosis (cell death), followed by accumulation of bacteria, 58 
which can then breach out to infect nearby cells.6 Therefore, drug resistant and 59 
intracellular S. aureus can result in incomplete eradication during therapy.  60 
 61 
 The control of S. aureus, particularly MRSA, is further complicated by the 62 
emergence of epidemic strains, which display increased virulence. These strains 63 
are reported to be highly invasive and able to cause bacteremia in patients.7 In 64 
 4 
the United Kingdom, epidemic methicillin-resistant S. aureus 15 (EMRSA-15) and 65 
EMRSA-16 strains constitute more than 60% and 35% of MRSA associated 66 
infections, respectively.7 These two strains are considered to be the most 67 
successful strains at surviving, colonising and spreading in the hospital 68 
environment.8-10 Similarly, in the United States (USA), strains USA 300 and USA 69 
400 often cause community-acquired MRSA infections, with USA 300 being the 70 
predominant cause of skin-and soft tissue infections.11 The USA 300 strain is 71 
widely disseminated across the USA and capable of causing clinical illness 72 
ranging from uncomplicated bacteremia to endocarditis, necrotising pneumonia, 73 
and osteomyelitis.12 74 
 75 
The recommended treatments for skin infection caused by S. aureus 76 
includes administration of topical and systemic antimicrobials.13 Topical 77 
administration is often needed to ensure drugs reach sites of infection. For 78 
example, in the case of burn injuries, damage to the local vascular system could 79 
limit oral antimicrobials distribution to infected sites. Therefore, topical 80 
antimicrobials such as mupirocin, fusidic acid, and bacitracin are frequently 81 
used.14 Unfortunately, increasing resistance to these antimicrobials has reduced 82 
effectiveness.15 Among the recently introduced topical antimicrobials, 83 
nadifloxacin, a fluoroquinolone, is effective against aerobic and anaerobic 84 
bacteria isolated from skin infections.16 Importantly, nadifloxacin is effective 85 
against ciprofloxacin resistant strains.17 Nadifloxacin is currently approved for 86 
acne treatment and skin infections.18 87 
 5 
Synthetic cationic polymers are becoming widely used in clinics as 88 
antimicrobials due to their broad-spectrum bactericidal activities and high 89 
therapeutic index. For example polyhexamethylene biguanide (PHMB) (Figure 1) 90 
is a cationic polymer that provides potent topical antimicrobial effects against 91 
Gram-positive and Gram-negative bacteria,19,20 fungi21,22 and certain viruses.23 92 
PHMB is a relatively safe compound with no reported adverse reactions when 93 
used on the skin, eyes, epithelium of the nose and wounds.24,25 It is available 94 
both as a disinfecting solution and impregnated into bio-cellulose dressings.26 95 
Although PHMB has been used in the clinic for more than 40 years, there are no 96 
reports of acquired resistance to this compound.24 Due to its excellent 97 
antibacterial properties and safety profile, PHMB is often administered topically to 98 
prevent wound infection.27 99 
 100 
Recently we observed that PHMB enters bacteria (Staphylococcus 101 
aureus, Escherichia coli and Mycobacterium smegmatis) and several types of 102 
mammalian cells grown in cell culture (including epithelial, macrophage and 103 
fibroblast cells).28,29 On the basis of these findings, and the established 104 
antibacterial properties of PHMB, we hypothesised that PHMB may also possess 105 
previously unrecognised antibacterial activity against intracellular bacteria. Here, 106 
we investigated the potential antibacterial activities of six topical antimicrobials 107 
and PHMB against intracellular MRSA. We further characterised the route(s) of 108 




Figure 1 Structure of PHMB 112 
PHMB is a cationic polymer of repeating hexamethylene biguanide groups, with n 113 
average = 10-12 (n is the number of structural unit repeats) and molecular weight 114 
(mw) 3025 gram/mol. 115 
  116 
 7 
 117 
MATERIALS AND METHODS 118 
Bacterial strains and growth conditions 119 
S. aureus strain RN4420 was obtained from Dr. Staffan Arvidson, Karolinska 120 
Institutet, Stockholm, Sweden,30 strain EMRSA-15 was obtained from Dr. Sean 121 
Nair, University College London,31 and strain USA 300 was obtained from Dr. 122 
Jonathan Otter, Imperial College Healthcare NHS Trust, UK.32 Bacteria were 123 
grown in Mueller Hinton Broth (MHB, Sigma-Aldrich, UK) followed by incubation 124 
at 250 rpm (for liquid cultures), at 37°C for 18 hours. 125 
 126 
Eukaryotic cell lines and growth conditions 127 
HaCaT cells were obtained from Dr. Amir Sharili, Queen Mary University of 128 
London and maintained in DMEM with 10% FBS (Sigma-Aldrich, UK), 129 
supplemented with 5% penicillin-streptomycin (Sigma-Aldrich, UK). Cells were 130 
maintained at 37°C in 5% carbon dioxide.  131 
 132 
Determination of minimum inhibitory concentrations (MIC) 133 
All antimicrobials were purchased from Sigma-Aldrich, UK, except nadifloxacin, 134 
which was from Santa Cruz Biotechnology, UK. PHMB and fluorescein-tagged 135 
PHMB (PHMB-FITC) were from Tecrea Ltd, UK. All antimicrobials were prepared 136 
in stock solution at 10, 000 mg/L. Fusidic acid, gentamicin, bacitracin and PHMB 137 
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were dissolved in sterile distilled water; mupirocin was dissolved in methanol; 138 
erythromycin was dissolved in ethanol and nadifloxacin was dissolved in 0.1M 139 
sodium hydroxide solution. 140 
 141 
MICs were determined using the broth microdilution method.33 Briefly, a 142 
range of concentrations of antimicrobials were prepared in a 96 well microplate, 143 
followed by inoculation of bacteria culture to yield ~5x105 cfu/mL in a 250 μl final 144 
volume. The plate was then incubated at 37°C for 18 hours. The lowest 145 
concentration of antimicrobial that inhibited growth of bacteria was scored as the 146 
MIC. 147 
 148 
Intracellular infection of keratinocytes by S. aureus  149 
Intracellular infection of keratinocytes by S. aureus RN4420, EMRSA-15 and 150 
USA 300 were established using a gentamicin protection procedure.34 151 
Keratinocytes were seeded at 1.2 x 105 cells/well in a 12 well plate and cultured 152 
overnight in DMEM with 10% FBS, without antibiotic. In parallel, all S. aureus 153 
strains were cultured overnight in MHB at 37°C in an incubator shaker. One mL 154 
of overnight bacterial culture was centrifuged at 8000 rpm for three minutes and 155 
the pellet was resuspended in phosphate buffered saline (PBS) (Sigma-Aldrich, 156 
UK). These steps were repeated three times to remove bacterial toxin residues. 157 
Bacteria were diluted to a final concentration of approximately 107 cfu/mL in 158 
DMEM with 10% FBS, without antibiotic. Aliquotes of bacteria (1 mL, 107 cfu/mL) 159 
were added to keratinocyte cultures after the original medium was removed. 160 
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Bacteria were coincubated with keratinocytes for three hours. 200 mg/L of 161 
gentamicin diluted in medium was added and incubated for three hours. Medium 162 
containing bacteria and gentamicin were removed and cells were rinsed with 163 
PBS. Rinse step was performed because this medium contained very high 164 
concentrations of gentamicin and therefore did not result in colony-forming units 165 
of bacteria when plated directly.  Therefore, aliquots of PBS from the rinsing 166 
process were plated on nutrient agar to determine the remaining number of 167 
extracellular bacteria. Next, one mL of 0.5% Triton X-100 prepared in PBS was 168 
added to each well to lyse cells. Lysed cells were serially diluted in PBS and 169 
plated on nutrient agar (Sigma-Aldrich, UK) for enumeration of intracellular 170 
bacteria. Uninfected cells were also subjected to the lysis procedure to confirm 171 
sterility.  172 
 173 
Visualisation of intracellular S. aureus within keratinocytes 174 
Keratinocytes were grown on glass cover slips in 12 well plates followed by 175 
EMRSA-15 infection as described above. Following gentamicin exposure to kill 176 
extracellular bacteria, cells were rinsed with PBS and fixed with 4% 177 
paraformaldehyde (Santa Cruz Biotechnology, UK). Cells were stained with 5 178 
mg/L DAPI (Life technologies, UK) for nuclei staining and 5 mg/L Wheat Germ 179 
Agglutinin-conjugated Alexa Fluor 555 (WGA, Life technologies, UK) for 180 
membrane staining. Cover slips were mounted onto glass slides with 181 
FluorSave™ (Calbiochem, UK). Images were visualised using a Leica SP5 182 
confocal microscope using Advanced Fluorescence Software (Leica 183 
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Microsystems, Milton Keynes, UK). Sequential scan Z-stacks (139 slices 1024 x 184 
1024) were compiled at a line average of 96, using Volocity® software. Three 185 
dimensional (3D) Image Analysis Software was used for analysis and to produce 186 
3D images.  187 
 188 
Intracellular killing activity of EMRSA-15 and USA 300 by nadifloxacin and 189 
PHMB  190 
Keratinocytes were infected with EMRSA-15 and USA 300 followed by incubation 191 
with gentamicin to kill extracellular bacteria. Following gentamicin exposure, 192 
keratinocytes were rinsed with PBS, and antimicrobials (nadifloxacin and PHMB 193 
in medium) were added to the wells containing infected cells. Plates were 194 
incubated for another three hours to kill intracellular bacteria. Following this 195 
period, antibiotic solutions were removed, cells were rinsed and lysed. Lysed 196 
cells were serially diluted and plated on nutrient agar. For each experiment, 197 
gentamicin treated cells (without nadifloxacin or PHMB treatments) were used as 198 
controls.  199 
 200 
Resazurin assay 201 
Keratinocytes (4 × 104 cells/well) were added to a 96 well plate and cultured with 202 
increasing concentrations of nadifloxacin or PHMB at 37°C for 24 hours. Non- 203 
treated cells and medium only were used as controls. Resazurin sodium salt 204 
(Sigma-Aldrich, UK) was prepared as a stock solution at 440 μM in PBS and 205 
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added to each well at 44 uM final concentration and plates were incubated for an 206 
additional 48 hours. Optical density (OD) was then measured using a Tecan 207 
Infinite plate reader (Tecan group Ltd, Switzerland) at 550 nm and 630 nm. The 208 
OD value change (or % dye reduction) is proportional to the viable cell number 209 
and was used to calculate half maximal inhibitory concentrations (IC50) values 210 
based on the intercept theorem. 211 
 212 
Visualisation and quantification of PHMB uptake into keratinocytes  213 
For both experiments, keratinocytes were grown on glass cover slips in a 12 well 214 
plate. PHMB-FITC was added to cultures at 4 mg/L for three hours. Cells were 215 
rinsed with PBS and stained as described above before confocal microscopy. To 216 
quantify PHMB uptake into keratinocytes, PHMB-FITC treated cells were 217 
incubated with 0.04% Trypan blue (Invitrogen, UK) in PBS for 15 minutes to 218 
quench membrane bounded PHMB-FITC, followed by flow cytometry (FACSBD 219 
machine and BDFACSDivaTM software, BD Bioscience) using the FITC filter. For 220 
each sample, 10,000 gated cells were analysed. 221 
 222 
Exocytosis of PHMB from keratinocytes  223 
Keratinocytes were seeded in 35 mm tissue culture treated dishes (Griener Bio- 224 
One, Austria). Keratinocytes were incubated with 4 mg/L of PHMB-FITC in 225 
medium for three hours. Following exposure, PHMB-FITC containing medium 226 
was removed and new medium containing 5 mg/L WGA was added. Fluorescent 227 
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quenching rates were determined and used to select an appropriate light 228 
intensity. Cellular fluorescence was monitored with images captured every 15 229 
minutes for five hours using confocal microscopy. Mean fluorescent intensity 230 
(MFI) was calculated at the beginning and after five hours of experiment to 231 
assess retention of PHMB-FITC in the cells.  232 
 233 
Statistical analysis 234 
All experiments were performed in triplicate. Statistical analysis was performed 235 
using one-way Analysis of Variance (ANOVA) followed by Tukey tests using the 236 
statistical packages Prism 6, Version 6.0 (GraphPad Prism 6.0, San Diego, CA). 237 
Data is presented as means ± standard deviation. Differences were considered 238 
to be statistically significant where p ≤ 0.05. For histogram and graphs, error bars 239 
represent standard deviations. *(p ≤ 0.05), *** (p ≤ 0.001), **** (p ≤ 0.0001), ns 240 
(not significant). 241 
  242 
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RESULTS 243 
Susceptibility of S. aureus strains to topically used antimicrobials and 244 
PHMB 245 
Six topically used antimicrobials were tested, and the MIC values for all six were 246 
higher for the clinical MRSA strains (EMRSA-15 & USA 300) than for the MSSA 247 
strain RN4420. In contrast, for PHMB, MIC values were similar for all strains. 248 
Overall, gentamicin, nadifloxacin and PHMB displayed the lowest MIC values 249 
against MRSA strains (Table 1).  250 
 251 
Given that nadifloxacin and PHMB displayed low MIC values relative to 252 
the other antimicrobials tested, we chose to focus on these two compounds in 253 
further studies. There are no reports for nadifloxacin and PHMB activities against 254 
intracellular bacteria. Gentamicin is an antibiotic that is active against 255 
extracellular bacteria, but not against intracellular bacteria, due to its poor 256 
penetration into mammalian cells.35 Therefore, we chose to further examine 257 
nadifloxacin and PHMB activities against intracellular MRSA, and gentamicin was 258 
not examined further.  259 
  260 
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Table 1 MIC values for topical antimicrobials against S. aureus RN4420, 261 
EMRSA-15 and USA 300 262 
MIC (mg/L) 
                    
Strains 
Antimicrobials 
RN4420 EMRSA-15 USA 300 
Mupirocin 0.125 32 2 
Fusidic acid 0.25 32 0.5 
Gentamicin 0.25 4 0.25 
Nadifloxacin 0.125 2 2 
Erythromycin 0.125 32 16 
Bacitracin 16 >32 32 
PHMB 1 1 1 
263 
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Intracellular invasion of keratinocytes by S. aureus  264 
To determine the activities of nadifloxacin and PHMB against intracellular 265 
bacteria, we first established an in vitro intracellular infection assay using MRSA 266 
and HaCaT cells.34  HaCaT is a well-established keratinocyte cell line that is often 267 
used experimentally as a host for intracellular S. aureus.6,36 To establish 268 
conditions for S. aureus RN4420, EMRSA-15 and USA 300 invasion in 269 
keratinocytes, bacteria were incubated with keratinocytes, followed by co- 270 
incubation with 200 mg/L of gentamicin to kill extracellular bacteria. All strains 271 
were able to invade keratinocytes, as indicated by their ability to evade 272 
gentamicin treatment. Three hours of infection followed by three hours of 273 
gentamicin treatment resulted in reproducible infections (Figure 2a, b & c). Killing 274 
of mainly extracellular bacteria was evident for all three strains, where lysis of 275 
keratinocytes following gentamicin exposure released approximately 103 cfu/mL 276 
of S. aureus RN4420, 105 cfu/mL of EMRSA-15 and 104 cfu/mL of USA 300. 277 
These colony counts presumably reflected S. aureus that were inside 278 
keratinocytes and thus protected from gentamicin’s extracellular antibacterial 279 
activities. As anticipated, the two clinical isolate strains, EMRSA-15 and USA 280 
300, showed higher invasion levels than S. aureus RN4420.  281 
 282 
S. aureus invasion of keratinocytes was visualised by confocal 283 
microscopy. Keratinocytes were infected with EMRSA-15 and stained with DAPI 284 
and WGA. Using 3D analysis, we observed localisation of EMRSA-15 (blue dots) 285 
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inside keratinocytes membranes (red) (Figure 3a & b), confirming invasion of 286 
EMRSA-15.  287 
 288 
 289 
Figure 2 S. aureus invasion in keratinocytes 290 
Colony forming units (cfu) of S. aureus following gentamicin exposure. After 291 
gentamicin exposure, lysis of keratinocytes released approximately 103 cfu/mL of 292 
S. aureus RN4420, 105 cfu/mL of EMRSA-15 and 104 cfu/mL of USA 300.  293 
  294 
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 295 
Figure 3 Localization of S. aureus in keratinocytes  296 
Invasion of EMRSA-15 in keratinocytes was visualized using confocal 297 
microscopy. Prior to imaging, keratinocytes were stained with DAPI (blue) for 298 
keratinocytes and EMRSA-15 nuclei staining and WGA (red) for keratinocyte 299 
membrane staining. Confocal microscopy z-stack projection moved through 139 300 
slices across keratinocytes. a) Horizontal cross-section of keratinocytes b) 301 
Ventricle cross-section of keratinocytes. The small blue dots are EMRSA-15 cells 302 
inside keratinocytes, indicating invasion. White scale bar is 7.5 μm.  303 
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Susceptibility of intracellular EMRSA-15 and USA 300 to nadifloxacin and 304 
PHMB 305 
To investigate the potential of nadifloxacin and PHMB to kill intracellular MRSA, 306 
keratinocytes were infected with EMRSA-15 and USA 300, exposed to 307 
gentamicin to kill extracellular bacteria, followed by treatment with nadifloxacin or 308 
PHMB at 1, 2, 4, 6, 8, 10 mg/L for three hours and enumeration of cfu of 309 
surviving intracellular bacteria. Figure 4 shows the percentages of surviving 310 
intracellular MRSA after treatment with nadifloxacin and PHMB, relative to 311 
untreated infected cells. Nadifloxacin at 10 mg/L killed 80% of intracellular 312 
EMRSA-15, but failed to kill USA 300 after three hours of treatment. PHMB at 4 313 
mg/L killed almost 100% of both strains as compared to 100% survival of the 314 
untreated infected cells. Therefore, while nadifloxacin displayed similar MIC 315 
values for both EMRSA-15 and USA 300; its activities were inconsistent against 316 
intracellular S. aureus, whereas, PHMB displayed consistent killing of both 317 
EMRSA-15 and USA 300.  318 
 19 
 319 
Figure 4 Bactericidal activities of nadifloxacin and PHMB against 320 
intracellular EMRSA-15 and USA 300  321 
Keratinocytes infected with EMRSA-15 and USA 300 were either untreated or 322 
treated with increasing concentrations of nadifloxacin or PHMB. Untreated 323 
cultures were used to establish cfu values corresponding to 100% survival.  324 
  325 
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Nadifloxacin and PHMB toxicity in keratinocytes 326 
Resazurin assays were performed to determine the in vitro toxicity levels of 327 
nadifloxacin and PHMB against keratinocytes. The IC50 values for nadifloxacin 328 
and PHMB were 1428 ± 247 mg/L and 19.7 ± 10 mg/L, respectively. Therefore, 329 
keratinocytes tolerated high concentrations of both compounds, which were far 330 
higher than the concentrations required to kill intracellular S. aureus; nadifloxacin 331 
(10 mg/L) and PHMB (4 mg/L). These results indicate that both compounds can 332 
be used to kill intracellular S. aureus with a high therapeutic index.  333 
 334 
PHMB uptake into keratinocytes 335 
Killing of intracellular S. aureus by antimicrobials normally requires drug entry 336 
into host cells and direct contact with bacteria. To test whether or not PHMB can 337 
enter keratinocytes, we added PHMB-FITC to cultures and tracked its 338 
intracellular localisation using confocal microscopy. As can be seen in Figure 5a, 339 
a mix of predominantly diffuse and small-punctuated spots of PHMB-FITC were 340 
observed. The diffuse signals suggest localisation in the cytosol, and the 341 
punctuated spots suggest localisation in vesicles. To quantify PHMB entry into 342 
keratinocytes, we analysed treated cells using flow cytometry. Consistent with 343 
microscopy results, flow cytometry data indicate that PHMB-FITC entered 99% of 344 
cells (Figure 5b).  345 
 346 
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Exocytosis of PHMB-FITC from keratinocytes 347 
Antimicrobial-mediated killing of intracellular pathogens may benefit from host 348 
cell retention. To determine PHMB’s host cell retention, we exposed 349 
keratinocytes to PHMB-FITC, rinsed the cells, added new medium and monitored 350 
cell-associated fluorescence over five hours. We observed only a minor reduction 351 
in fluorescence, with 90% of the fluorescence retained (Figure 5c & d). 352 
Therefore, the majority of PHMB was not excreted from cells, which may help to 353 
explain its potent killing of intracellular EMRSA-15 and USA 300.  354 
  355 
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 356 
Figure 5 PHMB-FITC uptake and retention in keratinocytes 357 
a) PHMB-FITC localization visualized by confocal microscopy. Free FITC was 358 
used as control. b) PHMB-FITC uptake was quantified by flow cytometry. The 359 
overlay histogram image illustrates the uptake of PHMB-FITC into keratinocytes. 360 
The red profile shows the population of keratinocytes treated with FITC and 361 
serves as a negative control. The green profile shows the population of 362 
keratinocytes treated with PHMB-FITC. Uptake of PHMB-FITC was observed in > 363 
99% keratinocytes. c) Keratinocytes following treatment with PHMB-FITC and 364 
five hours after rinsing to remove extracellular PHMB-FITC. d) Mean 365 
fluorescence intensity (MFI) of PHMB-FITC before and after five hours of 366 
experiments.  367 
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Colocalisation of PHMB and EMRSA-15 in keratinocytes 368 
The results described above are most easily explained by a mechanism of direct 369 
killing of EMRSA-15 and USA 300, where PHMB enters keratinocytes and then 370 
kills bacteria. However, other indirect killing mechanisms are formally possible. 371 
To further characterise the PHMB-mediated killing mechanism(s), localisation of 372 
EMRSA-15 and PHMB-FITC inside keratinocytes was assessed using the 373 
gentamicin protection method together with microscopy. After gentamicin 374 
treatment, PHMB-FITC was added to cells, and after three hours of incubation, 375 
cells were rinsed and stained with DAPI and WGA. Cells were then fixed and 376 
imaged using confocal microscopy. 377 
 378 
Colocalisation of blue-stained bacteria and green PHMB-FITC was 379 
apparent inside host cells, as shown in figure 6. Indeed, colocalisation of PHMB- 380 
FITC and EMRSA-15 in keratinocytes was apparent for the majority of 381 
intracellular bacteria in all cells examined. Therefore, PHMB-FITC appears to 382 
directly access intracellular EMRSA-15 inside keratinocytes, suggesting direct 383 




Figure 6 Colocalization of PHMB-FITC with EMRSA-15 in keratinocytes  
Keratinocytes were infected with EMRSA-15 followed by treatment with PHMB-FITC (green). Prior to microscopy, keratinocytes 
were labeled with DAPI (blue) and WGA (red). Upper panels are images of infected cells visualized using filters for DAPI, FITC 
and WGA, and merged images. Lower panels are enlarged images that clearly show colocalization between PHMB-FITC 
(green) and EMRSA-15 (blue). White scale bar is 25 μm. 
 25 
Effect of dynamin inhibition on PHMB uptake and antibacterial activity in 1 
keratinocytes 2 
Cell entry pathways that transport PHMB and S. aureus to a common final 3 
destination in the cell could explain their colocalisation in keratinocytes. Recent 4 
work in our laboratory demonstrates that PHMB enters macrophage 5 
predominantly via a dynamin-dependent endocytic pathway.28 This pathway 6 
requires dynamin (a GTPase) to excise newly formed vesicle from the 7 
membrane.37 Without dynamin-mediated vesicle excision, vesicles do not form 8 
and enter cell. 9 
 10 
If PHMB kills intracellular S. aureus via direct contact with bacteria in 11 
keratinocytes, as suggested by colocalisation results above, then inhibitors that 12 
block cell entry should reduce both PHMB uptake and intracellular killing. To test 13 
the effect of dynamin inhibition on PHMB uptake, we pre-treated keratinocytes 14 
with a dynamin inhibitor, dynasore before addition of PHMB-FITC. Using confocal 15 
microscopy, we observed that dynasore reduced PHMB-FITC uptake (Figure 7a). 16 
Quantification using flow cytometer confirmed that dynasore reduced PHMB- 17 
FITC uptake into keratinocytes by 85% (Figure 7b). Similarly, dynasore reduced 18 
PHMB-mediated killing of intracellular EMRSA-15 by approximately 50% (Figure 19 
7c). These results suggest that PHMB entry and intracellular antibacterial activity 20 
in keratinocytes involves dynamin-dependent endocytic pathways. 21 
  22 
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 23 
Figure 7 Effects of dynasore on PHMB uptake into keratinocytes and killing 24 
of intracellular EMRSA-15   25 
Uptake of PHMB and intracellular antimicrobial activities in dynasore pre-treated 26 
keratinocytes. Cells were pre-treated with dynasore (in 0.5% DMSO) for 30 27 
minutes. Then cells were incubated with PHMB-FITC for uptake studies or PHMB 28 
for antimicrobial activity studies. “Control” samples were keratinocytes treated 29 
with PHMB-FITC alone. “Vehicle” samples were keratinocytes treated with 30 
PHMB-FITC in media containing 0.5% DMSO. Following treatment, keratinocytes 31 
were: a) visualized by confocal microscopy and b) analyzed by flow cytometer. c) 32 
Effects of dynasore on PHMB-mediated killing of intracellular bacteria.   33 
 27 
DISCUSSION 34 
Intracellular bacteria are typically difficult to kill because they are shielded from 35 
host immune mechanisms and protected from antimicrobials. Here, we found that 36 
nadifloxacin and PHMB kill intracellular MRSA within keratinocytes, with PHMB 37 
being more potent. Nadifloxacin-mediated killing of intracellular S. aureus is 38 
perhaps expected, because it is a small molecule belonging to the 39 
fluoroquinolone group, a class of antibiotic that can enter and accumulate within 40 
mammalian cells.38 However, nadifloxacin displayed inconsistent activity; being 41 
effective against EMRSA-15 but not against USA300. In contrast, the intracellular 42 
activity of PHMB was unexpected, because it is a relatively large molecule 43 
(average molecular weight around 3025 grams/mol)39 and has only recently been 44 
reported to enter mammalian cells.28,29 Nevertheless, our results clearly show 45 
that PHMB enters keratinocytes and is retained for several hours.  46 
 47 
Intracellular pathogens such as S. aureus enter mammalian cells through 48 
phagocytosis (one of the endocytic pathways) via a zipper-uptake mechanism.40 49 
Inside host cells, the fate of S. aureus is to be killed by innate immune 50 
mechanisms within a phagolysosome, replicate inside an endosome, or escape 51 
into the cytosol.40 Inside keratinocytes, the polymer PHMB-FITC localises mainly 52 
inside vesicles and in the cytosol. In this study, we observed colocalisation 53 
between PHMB-FITC and almost all intracellular EMRSA-15, suggesting direct 54 
interactions that could occur in both vesicles and the cytosol. These interactions 55 
may explain the potent intracellular bactericidal activities of PHMB. Furthermore, 56 
 28 
inhibition of dynamin, a GTPase which pinches-off newly formed endocytic 57 
vesicles from the membrane,37 impeded both PHMB-FITC uptake and its 58 
intracellular killing activity. Therefore, PHMB uptake into keratinocytes appears to 59 
be dynamin-dependent. 60 
 61 
There are three main findings from this study. First, both nadifloxacin and 62 
PHMB are effective against intracellular S. aureus with PHMB being more potent 63 
against intracellular MRSA. Second, PHMB colocalises with intracellular MRSA 64 
in keratinocytes, indicating that killing occurs by direct interactions inside host 65 
cells. Third, PHMB’s uptake and antibacterial activities inside keratinocytes 66 
appear to involve a dynamin-dependent cell uptake mechanism. Together, these 67 
findings suggest that nadifloxacin and particularly PHMB have previously 68 
unrecognised potential for treating skin infections caused by intracellular MRSA 69 
and possibly other intracellular bacteria.  70 
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